TuHURA Adds Seasoned Clinical Ops Exec Amidst Key Trial Milestones
Event summary
- TuHURA Biosciences appointed Amanda Garofalo as Senior Vice President of Clinical Operations, effective immediately.
- Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development.
- She previously held leadership roles at Parabilis Medicines, EMD Serono, Arcus Biosciences, Indivior, Medimmune, and GlaxoSmithKline Pharmaceuticals.
- Garofalo will work closely with Dr. Craig Tendler and oversee clinical operations for IFx-2.0 (Phase 3), TBS-2025 (Phase 1b/2), and early-stage ADCs.
The big picture
TuHURA’s appointment of a seasoned clinical operations executive signals a focus on accelerating its pipeline, particularly as it approaches a critical Phase 3 trial for IFx-2.0. The company's acquisition of Kineta and TBS-2025 adds complexity to its portfolio, requiring strong operational leadership to manage diverse programs. This hire suggests TuHURA is proactively addressing the challenges of scaling clinical operations to support multiple development programs and potential regulatory submissions.
What we're watching
- Execution Risk
- Garofalo's experience will be critical as TuHURA navigates the accelerated approval pathway for IFx-2.0 and the complexities of advancing TBS-2025 into Phase 1b/2.
- Clinical Trial Enrollment
- Given Garofalo’s prior experience, how effectively she can optimize enrollment rates across TuHURA’s trials will be a key indicator of progress.
- ADC Development
- The company’s plans for ADC development are nascent; the speed at which these programs advance will reflect the integration of Garofalo’s expertise and the allocation of resources.
Related topics